PRINCETON, N.J., Sept. 26, 2017 /PRNewswire/ -- PM360, a publication for marketing decision makers in the pharma/biotech and medical device industries, has named Promius Pharma the Silver Winner Trailblazer Specialty Pharma/Biotech company of the year. Winning companies are selected based on their ability to excel in innovation, talent development, and social responsibility.
"Our colleagues strive to bring relevant solutions to providers so they may help their patients in their journey to well-being," says Dushyanth Surakanti, Senior Vice President, Chief Commercial Officer and Head of Corporate Development. "This recognition is not only a testament to our mission, but also the tireless efforts of our R&D and sales and marketing colleagues over the past several years."
About Promius Pharma LLCPromius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology. For more information, visit www.promiuspharma.com.
Contact information:Promius Pharma, LLC107 College Rd EPrinceton, NJ 08540 www.promiuspharma.com
MEDIA RELATIONS:Lori McCreary (USA)[email protected]+1 (609) 375-2995
INVESTOR RELATIONSAshish Girotra[email protected](Ph: +1 6093756145)
Copyright 2017 Promius Pharma, LLC
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues. The company assumes no obligation to update any information contained herein.
Advertisement
"Our colleagues strive to bring relevant solutions to providers so they may help their patients in their journey to well-being," says Dushyanth Surakanti, Senior Vice President, Chief Commercial Officer and Head of Corporate Development. "This recognition is not only a testament to our mission, but also the tireless efforts of our R&D and sales and marketing colleagues over the past several years."
Advertisement
About Promius Pharma LLCPromius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology. For more information, visit www.promiuspharma.com.
Contact information:Promius Pharma, LLC107 College Rd EPrinceton, NJ 08540 www.promiuspharma.com
MEDIA RELATIONS:Lori McCreary (USA)[email protected]+1 (609) 375-2995
INVESTOR RELATIONSAshish Girotra[email protected](Ph: +1 6093756145)
Copyright 2017 Promius Pharma, LLC
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues. The company assumes no obligation to update any information contained herein.
View original content:http://www.prnewswire.com/news-releases/promius-pharma-named-pm360-silver-winner-trailblazer-specialty-pharmabiotech-company-of-the-year-300525284.html
SOURCE Promius Pharma LLC
